臨床検査57巻3号

2013年03月発行

今月の特集1 分子病理診断の進歩

CD20

著者： 冨田章裕¹

所属機関： ¹名古屋大学大学院医学系研究科血液・腫瘍内科学

ページ範囲：P.278 - P.286

■CD20はB細胞表面に特異的に発現する表面抗原で，造血幹細胞や形質細胞には発現しない．

■リツキシマブは第1世代の抗CD20モノクローナル抗体治療薬で，現在B細胞性リンパ腫に対する標準的な治療薬とされている．治療効果を高めた第2，3世代の治療薬も開発されている．

■CD20発現低下によるリツキシマブ耐性が実臨床で経験されている．

参考文献

1）Harris NL, Jaffe ES, Diebold J, et al：World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol　17：3835-3849，1999

2）Stashenko P, Nadler LM, Hardy R, et al：Characterization of a human B lymphocyte-specific antigen. J Immunol　125：1678-1685，1980

3）Ishii Y, Takami T, Yuasa H, et al：Two distinct antigen systems in human B lymphocytes: identification of cell surface and intracellular antigens using monoclonal antibodies. Clin Exp Immunol　58：183-192，1984

4）Mason DY, Comans-Bitter WM, Cordell JL, et al：Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol　136：1215-1222，1990

5）Einfeld DA, Brown JP, Valentine MA, et al：Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J　7：711-717，1988

6）Tedder TF, Klejman G, Schlossman SF, et al：Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol　142：2560-2568，1989

7）Swerdlow SH, Campo E, Harris NL, et al：WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, WHO Press, Geneva，2008

8）Walshe CA, Beers SA, French RR, et al：Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem　283：16971-16984，2008

9）Tedder TF, Schlossman SF：Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem　263：10009-10015，1988

10）Prevodnik VK, Lavrenčak J, Horvat M, et al：The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol　6：33，2011

11）Coiffier B, Lepage E, Briere J, et al：CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med　346：235-242，2002

12）Salles G, Seymour JF, Offner F, et al：Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet　377：42-51，2011

13）Cang S, Mukhi N, Wang K, et al：Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol　5：64，2012

14）Niederfellner G, Lammens A, Mundigl O, et al：Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood　118：358-367，2011

15）Cragg MS：CD20 antibodies：doing the time warp. Blood　118：219-220，2011

16）Lim SH, Beers SA, French RR：Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica　95：135-143，2010

17）Niederfellner GJ, Lammens A, Schwaiger M, et al：Crystal structure analysis reveals that the novel type II anti-CD20 antibody GA101 interacts with a similar epitope as rituximab and ocrelizumab but in a fundanentally different way. Blood (ASH Annual Meeting Abstracts)　114：3726，2009

18）Binder M, Otto F, Mertelsmann R, et al：The epitope recognized by rituximab. Blood　108：1975-1978，2006

19）Hiraga J, Tomita A, Sugimoto T, et al：Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood　113：4885-4893，2009

20）Lim SH, Beers SA, French RR, et al：Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica　95：135-143，2010

21）Tomita A, Hiraga J, Kiyoi H, et al：Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol　86：49-57，2007

22）Sonoki T, Li Y, Miyanishi S, et al：Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab. Int J Hematol　89：400-402，2009

23）van Meerten T, van Rijn RS, Hol S, et al：Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res　12：4027-4035，2006

24）Patz M, Isaeva P, Forcob N, et al：Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol　152：295-306，2011

25）Czuczman MS, Fayad L, Delwail V, et al：Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood　119：3698-3704，2012